Orthos

Orthos Therapeutics is a biotechnology company based in the Netherlands that specializes in the development of VHH-based therapeutics (nanobodies) for chronic inflammatory and musculoskeletal diseases. The company's core technology focuses on a proprietary platform that enables the specific targeting of therapeutic compounds to diseased tissues, such as cartilage in joints, to improve efficacy and reduce systemic side effects. Their lead programs are primarily focused on treating osteoarthritis, a condition with significant unmet medical needs and limited disease-modifying options. By leveraging the unique properties of single-domain antibodies, Orthos aims to deliver localized treatment that can halt or reverse tissue degeneration. The company is currently in the pre-clinical stage, advancing its pipeline toward first-in-human trials.